Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/502
Title: Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men
Authors: ANDERSON, Peter L.GLIDDEN, David V.LIU, AlbertBUCHBINDER, SusanLAMA, Javier R.GUANIRA, Juan VicenteMCMAHAN, VanessaBUSHMAN, Lane R.CASAPIA, MartinMONTOYA-HERRERA, OrlandoVELOSO, Valdilea G.MAYER, Kenneth H.CHARIYALERTSAK, SuwatSCHECHTER, MauroBEKKER, Linda-GailKALLAS, Esper GeorgesGRANT, Robert M.
Citation: SCIENCE TRANSLATIONAL MEDICINE, v.4, n.151, article ID 151ra125, 8p, 2012
Abstract: Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We evaluated drug concentrations among men who have sex with men in a substudy of the iPrEx trial (1). In this randomized placebo-controlled trial, daily oral doses of emtricitabine/tenofovir disoproxil fumarate were used as pre-exposure prophylaxis (PrEP) in men who have sex with men. Drug was detected less frequently in blood plasma and in viable cryopreserved peripheral blood mononuclear cells (PBMCs) in HIV-infected cases at the visit when HIV was first discovered compared with controls at the matched time point of the study (8% versus 44%; P < 0.001) and in the 90 days before that visit (11% versus 51%; P < 0.001). An intracellular concentration of the active form of tenofovir, tenofovir-diphosphate (TFV-DP), of 16 fmol per million PBMCs was associated with a 90% reduction in HIV acquisition relative to the placebo arm. Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week. Pro-phylactic benefits were observed over a range of doses and drug concentrations, suggesting ways to optimize PrEP regimens for this population.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/60
LIM/60 - Laboratório de Imunologia Clínica e Alergia


Files in This Item:
File Description SizeFormat 
art_KALLAS_Emtricitabine_Tenofovir_Concentrations_and_Pre_Exposure_Prophylaxis_Efficacy_2012.PDF
  Restricted Access
publishedVersion (English)390.17 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.